Cytek BioSciences Inc risk profile
65 Stretched several inputs deteriorating together
Measured 21 October 2026 from CTKB's filed statements. Recomputed nightly.
65 (Stretched), driven by Cash conversion at 90, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 50 | Elevated | Volatile | One-year price volatility — 55.7% |
| Operating pressure | 75 | Stretched | Worsening | Costs outgrowing revenue — +8.9 percentage points |
| Cash conversion | 90 | Acute | Worsening | Capital spending against operating cash — -0.87x |
| Leverage and coverage | 35 | Normal | Worsening | Interest cover — -69.21x |
| Competitive position | 79 | Stretched | Stable | Operating-margin gap against peers — -20.6 percentage points |
| Concentration | 44 | Elevated | Stable | Geographic concentration — 3,420 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Cytek BioSciences Inc